Biotech IV Monitor

DYN — Dyne Therapeutics Inc.

$4.5B market cap · 4 upcoming readouts tracked

Clinical trial readout dates for Dyne Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is July 2028.

Next readoutJuly 2028in ~20 months
Upcoming readouts42 Phase 3
Market cap$4.5B
Cash & investments$1.13B~6 quarters at last loss rate
Recent 8-K filings1latest 2026-11-05

Upcoming readouts

Phase 3 zeleciment basivarsen (DYNE-101)
Myotonic Dystrophy Type 1 (DM1); DM1 · NCT07486934
July 2028
Recruiting
Phase 1/2 DYNE-101
Myotonic Dystrophy Type 1 (DM1) · NCT05481879
July 2029
Ongoing
Phase 3 Zeleciment Rostudirsen (DYNE-251)
Duchenne Muscular Dystrophy (DMD); Muscular Dystrophy, Duchenne · NCT07608432
December 2030
Recruiting
Phase 1/2 DYNE-251
Duchenne Muscular Dystrophy (DMD) · NCT05524883
September 2031
Ongoing

Cash position

Dyne Therapeutics Inc. reported $1.13B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-05). Its net loss for that quarter was $194M; at that rate the cash would last about 6 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-05

Companies working on similar indications

Discussion

No messages yet. If you follow DYN, you can start the conversation.
Track DYN in real time
See live implied volatility for DYN and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on DYN
Contact — questions or corrections about DYN: dukeupt@gmail.com